After being approved for Eczema, Regeneron's and Sanofi's product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma. - Prohost Biotech - Exclusive Biotech Research
Exclusive Market Insight
& Scientific analysis
Subscribe today
Exclusive Posts
Industry Newsletters
Clinical Trials
Possible Takeovers
Technology of the Week
Stock Table
Therapeutic Vaccines
Development-Stage Firms
Genomics
Prohost Picks
And much more...
Menu
Home
News & Comments
Today’s Highlights
The Week in Review
Prohost Letters
Contact Us
Login / Register
Login
Register
Home
News & Comments
Today’s Highlights
The Week in Review
Prohost Letters
Contact Us
Login / Register
Login
Register
Home
Today’s Highlights
After being approved for Eczema, Regeneron’s and Sanofi’s product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma.
After being approved for Eczema, Regeneron’s and Sanofi’s product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma.
Today’s Highlights
Regeneron (REGN), Sanofi (SNA)
October 16, 2018
In two pivotal Phase 3 placebo-controlled trials Regeneron Pharmaceuticals’ (REGN) and Sanofi’s (SNY) drug, Dupixent® (dupilumab), demonstrated a significant reduction in nasal polyp size, nasal congestion’s severity and the need for systemic corticosteroids and/or surgery.
Both trials were evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps (CRSwNP). They both met met all their primary and secondary endpoints.
Dupixent is a monoclonal antibody designed to target and block IL-4 and IL-13 signaling pathways . . .
This content is for paid subscribers.
Please click here to subscribe or here to log in.
Tweet Pin It
Other Articles
Novartis: More promising data from a Phase 3 trial with AveXis’ gene therapy Zolgensma® for Spinal Muscular Atrophy Type 1
April 17, 2019 0
Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture
April 10, 2019 0
The Amgen/Novartis story. A little curiosity about Alder Biopharmaceuticals.
April 8, 2019 0
Novartis’ Revolution: A new dimension and Prohost expectations
April 1, 2019 0
Search Prohost
Recent
Popular
Tag Cloud
Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam (ALNY) Amgen (AMGN) Arbutus Biopharma (ABUS) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) CompuGen (CGEN) CRISPR Therapeutics (CRSP) CytomX Therapeutics Inc (CTMX) Editas Medicine Inc (EDIT) Enanta (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Innoviva (INVA) Intellia Therapeuctics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Nektar Therapeutics (NKTR) Neurocrine Biosciences (NBIX) Newlink Genetics (NLNK) Novartis (NVS) Ophthotech Corporation (OPHT) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron (REGN) RegenxBio (RGNX) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seattle Genetics (SGEN) Spectrum Pharmaceuticals (SPPI) Sunesis Pharmaceuticals (SNSS) Theravance Biopharma (TBPH) Vertex (VRTX) Xoma (XOMA)
Prohost Biotech – Exclusive Biotech Research Copyright © 2019.
© 2014 Prohost Biotech. All rights reserved.
Privacy Policy | Cancellation Policy | Forward Looking Statement
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy